Repligen Corporation (NASDAQ:RGEN) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Repligen Corporation (NASDAQ:RGEN) has been given a consensus rating of "Moderate Buy" by 15 analysts, with an average 12-month price target of approximately $169.62.
• Notable changes in analyst ratings include Wells Fargo lowering its price target to $175, while Evercore ISI raised it to $175 as well.
• Institutional ownership of Repligen is high at 97.64%, with significant recent increases from several investors, such as GAMMA Investing and Fifth Third Bancorp.

Repligen Corporation (NASDAQ:RGEN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fifteen ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $169.6154.

A number of research analysts have commented on RGEN shares. Wells Fargo & Company lowered their price target on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday, July 30th. Evercore ISI increased their target price on Repligen from $155.00 to $175.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 7th. Wall Street Zen raised Repligen from a "hold" rating to a "buy" rating in a research report on Saturday. Stephens raised Repligen to an "overweight" rating and set a $160.00 target price for the company in a research report on Tuesday, July 22nd. Finally, Hsbc Global Res raised Repligen to a "strong-buy" rating in a research report on Wednesday, October 1st.

Insider Activity

In other news, Director Martin D. Madaus bought 1,800 shares of the firm's stock in a transaction dated Friday, August 8th. The stock was purchased at an average price of $112.13 per share, with a total value of $201,834.00. Following the transaction, the director owned 1,800 shares of the company's stock, valued at approximately $201,834. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.20% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in RGEN. GAMMA Investing LLC increased its position in Repligen by 40.1% during the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock valued at $122,000 after buying an additional 274 shares in the last quarter. Fifth Third Bancorp increased its position in Repligen by 34.4% during the 1st quarter. Fifth Third Bancorp now owns 5,734 shares of the biotechnology company's stock valued at $730,000 after buying an additional 1,467 shares in the last quarter. QRG Capital Management Inc. increased its position in Repligen by 8.8% during the 1st quarter. QRG Capital Management Inc. now owns 2,548 shares of the biotechnology company's stock valued at $324,000 after buying an additional 206 shares in the last quarter. Conestoga Capital Advisors LLC increased its position in Repligen by 3.4% during the 1st quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company's stock valued at $124,727,000 after buying an additional 32,665 shares in the last quarter. Finally, State of Alaska Department of Revenue increased its position in Repligen by 2.8% during the 1st quarter. State of Alaska Department of Revenue now owns 6,104 shares of the biotechnology company's stock valued at $776,000 after buying an additional 165 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Repligen Trading Up 2.4%

RGEN opened at $148.67 on Tuesday. The business has a 50 day simple moving average of $125.77 and a two-hundred day simple moving average of $125.65. The firm has a market capitalization of $8.36 billion, a price-to-earnings ratio of -594.66, a PEG ratio of 2.68 and a beta of 1.08. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. Repligen has a one year low of $102.96 and a one year high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The business had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company's revenue for the quarter was up 14.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Analysts predict that Repligen will post 1.72 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.